MedPath

Trial Examining Methods for Antidepressant Discontinuatio

Phase 4
Recruiting
Conditions
10012375
<p>Major Depressive Disorder</p>
Paroxetine, venlafaxine, discontinuation, tapering, hyperbolic
Registration Number
NL-OMON29528
Lead Sponsor
AmsterdamUMC
Brief Summary

tba

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
200
Inclusion Criteria

src=https://www.toetsingonline.nl/icons/ecblank.gif Om in aanmerking te komen voor deelname aan dit onderzoek, moet een proefpersoon aan alle volgende criteria voldoen:

• Leeftijd 18-75 jaar

Exclusion Criteria

Een potentiële proefpersoon die aan een van de volgende criteria voldoet, wordt uitgesloten van deelname aan dit onderzoek:

• Psychotische/bipolaire stoornis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The number of patients who are unable to successfully continue to taper the PAR or VLX and stop taking study-medication or take rescue medication</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>- Withdrawal symptom severity over time (DESS-score) - Depressive symptoms over time (IDS-SR) - Relapse/recurrence rate (MDD diagnosis on MINI interview) and time to event during follow-up - Daily functioning and Quality of life (EQ-5D-5L) - Attitudes towards and perceived difficulty of discontinuation (patient reported) - Cost-effectiveness and productivity losses (TiC-P) - Before and after discontinuation choice and decision times on a task requiring participants to choose how much effort to exert for various amounts of reward</p><br>
© Copyright 2025. All Rights Reserved by MedPath